7/27/2019 JOURNAL Breast Cancer

1/10

This Provisional PDF corresponds to the article as PDF and full text (HTML) versions

MiR-34b is associated with clinical outcopatien

Diagnostic Pathology2012,7:31

Marek Svoboda (msvo

Diagnostic Pathology

mailto:msvoboda@mou.czmailto:msvoboda@mou.cz

7/27/2019 JOURNAL Breast Cancer

2/10

MiR-34b is associated with clini

negative breast cancer patients

Marek Svoboda,Aff1

Corresponding Affiliation: Aff1

Email: msvoboda@mou.cz

Jiri Sana,Aff1

Email: sana.jiri@gmail.com

7/27/2019 JOURNAL Breast Cancer

3/10

Methods

Thirty-nine TNBC patients with available formalin

were enrolled in the study. MiR-34a, miR-34b, an

and correlated to clinico-pathological features of T

Results

Expression levels of miR-34b significantly correla

(p = 0.0020, log-rank test) and overall survival (OSi h i ifi i i b

7/27/2019 JOURNAL Breast Cancer

4/10

can be used to predict a therapeutic response and c

rationalize treatment decisions.

MicroRNAs (miRNAs) are highly conserved, sma

length, that act as posttranscriptional regulators of

targets. Recent studies showed that miRNAs regul

tumor suppressor genes, and genes associated with

chemoresistance of tumors. Therefore, these mole

pathogenesis of many cancers, including the breas

[8,9]. Many recent works described that the gene pmutations in TNBC patients activates transcriptio

7/27/2019 JOURNAL Breast Cancer

5/10

T

1 10

2 21

3 4

4 4

N

0 17

1 13

2 7

7/27/2019 JOURNAL Breast Cancer

6/10

the Taq-Man MicroRNA Assay protocol (Applied

performed using the Applied Biosystems 7500 Re

the TaqMan MicroRNA Assay protocol. Reverse tdetection were carried out using hsa-miR-34a, hsa

4427975; Applied Biosystems, USA). RNU6B (A

USA) was used as a reference gene. The threshold

default threshold settings.

Statistical analysis

Statistical analysis of differences of miRNA expre

7/27/2019 JOURNAL Breast Cancer

7/10

view, it is one of the features of TNBCs that is poo

expression could also be a marker of differentiatio

assumption is also supported by the fact that miR-direct regulator of Notch2 which plays an importa

decreased in breast cancer tumors with poor differ

[20]. In breast cancer, Notch2 pathway is also a po

effect on tumor growth in xenograft model [21]. R

revealed that overexpression of another member o

an aggressive breast tumor phenotype (positive no

rate, high grade, p53-positivity) [22]. Moreover, D

miR-34a significantly suppressed proliferation of M

7/27/2019 JOURNAL Breast Cancer

8/10

References

1. Bertos NR, Park M: Breast cancer - one term

121:37893796.

2. Voduc KD, Cheang MC, Tyldesley S, Gelmon

cancer subtypes and the risk of local and region

1691.

3. Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Sh

7/27/2019 JOURNAL Breast Cancer

9/10

14. Hiroki E, Suzuki F, Akahira JI, Nagase S, Ito

H, Yaegashi N: MicroRNA-34b functions as a p

serous adenocarcinoma.Int J Cancer2012, in pr

15. Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, T

MicroRNA 34b as a tumor suppressor in estrog

cells.Breast Cancer Res2011, 13:R116.

16. Katada T, Ishiguro H, Kuwabara Y, Kimura M

Fujii Y: microRNA expression profile in undiffe

2009 34:537542

7/27/2019 JOURNAL Breast Cancer

10/10Figure 1